|
6th Annual Future of Clinical Trials
26 October 2010
Leading Pharmaceutical players understand, how to complete trials with greater levels of cost efficiency, timelines and success. Reveal how to tailor clinical trials to the needs of the patients. Join us & discuss with leading Pharma companies.
|
|
|
|
TGen Affiliate, Van Andel Research Institute, Joins with Spectrum Health and Oncology Group
30 July 2010
Cancer patients in West Michigan will soon have the opportunity to access new drugs being developed to fight their disease due to a partnership being formed in Grand Rapids.
|
|
|
|
Trophos Publishes the Identification and Characterization of Cardioprotective Compound, TRO40303
29 July 2010
JPET publication describes latest Trophos mitochondrial pore modulator now entering clinical development in cardiology.
|
|
|
|
Bionan Healthcare Partners with Bilcare GCS on Critical Clinical Venture
29 July 2010
Partnership offers the complete success of the fulfillment of clinical trial project objectives.
|
|
|
|
CMS Approves Clinical Study of Genetic Test to Predict Patient Response to Warfarin
27 July 2010
Study to evaluate gene identification ability to predict patient response and improve safety when dosing this anti-blood clotting drug.
|
|
|
|
Genticel’s Therapeutic Vaccine, ProCervix for HPV Receives Clearance to Start a Phase I Clinical Trial
26 July 2010
Entry into Phase I marks a significant milestone for Genticel, which completed a EUR 13.1 million fund-raising in February 2010.
|
|
|
|
PharmaNet Development Group Collaborates with Abacus International
26 July 2010
Collaboration is aimed to support patient registries and health economic programs in Europe.
|
|
|
|
Wake Forest Researchers Use Nanoparticles as Destructive Beacons to Zap Tumors
23 July 2010
Researchers are developing a way to treat cancer by using lasers to light up tiny nanoparticles and destroy tumors with the ensuing heat.
|
|
|
|
Algeta Concludes Agreements for the Manufacture and Supply of Alpharadin for Future Commercial Sale
23 July 2010
The signing of these agreements triggers a EUR 5 million milestone payment from Bayer Schering Pharma.
|
|
|
|
NIH-Funded Study Finds Early Haart During TB Treatment Boosts Survival Rate in People Co-Infected with HIV and TB
23 July 2010
Findings presented at the XVIII International AIDS Conference will help in optimizing treatment of individuals infected with HIV-TB co-infection.
|
|
|
|
Medical Device Consultants, Inc. and Clinical Development & Support Services Ltd Announce Strategic Partnership
22 July 2010
Collaboration will support medical device clinical trial design and conduct in US and Europe.
|
|
|
|
Oncolytics Biotech® Inc. Receives No Objection Letter from Health Canada to Conduct Phase 3 Trial of REOLYSIN®
22 July 2010
The company plans to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with head and neck cancers.
|
|
|
|
AiCuris Presents Mechanism of Action Investigations of its Anti-HCMV Drug AIC246
22 July 2010
Company announce publication of preclinical data on AIC246, at the International Herpesvirus Workshop in Salt Lake City, Utah.
|
|
|
|
Global Data release new market report forecasting the potential opportunities in the Neuropathic Pain Market
21 July 2010
Global Data's 'Neuropathic Pain - Pipeline Assessment and Market Forecasts to 2016' report, sets out to identify the key trends shaping and driving the global neuropathic pain market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to bring significant shifts in the positioning of the existing market leaders.
|
|
|
|
Encorium Group Acquires Progenitor International Research
21 July 2010
The acquisition gives Encorium capabilities to run clinical trials in South America, India and Asia Pacific.
|
|
|
|
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets Pre-Specified Endpoint
21 July 2010
PROGRESS is said to be the first study to present 48-week efficacy results for this combination when used in treatment-naive patients with HIV.
|
|
|
|
New Drugs Target Alzheimer’s Disease
16 July 2010
Rapidly growing immunotherapy pipeline offers hope of disease-altering therapies.
|
|
|
|
Peregrine Initiates Second Randomized Phase IIb Lung Cancer Trial Using PS-Targeting Monoclonal Antibody Bavituximab
15 July 2010
Promising tumor response and median PFS data reported at ASCO lead to new Phase IIb trial.
|
|
|
|
Molecular Insight Pharmaceuticals' Zemiva Phase 2 Data Published in Journal of the American College of Cardiology
15 July 2010
Researchers confirm that addition of Zemiva to available clinical information contributes to the early diagnosis and evaluation of acute coronary syndrome.
|
|
|
|
NIH Expands National Network for Transforming Clinical and Translational Research
15 July 2010
Nine Institutions to receive $255 million over five years to help scientists bridge laboratory discoveries to patient treatments.
|
|
|
|
CTI Signs Long-Term Manufacturing Agreement for Pixantrone with NerPharMa
14 July 2010
CTI plans marketing authorization application filing in Europe this year.
|
|
|
|
Immunovaccine Licenses Clinical Stage Cancer Vaccine from Merck KGaA
13 July 2010
Immunovaccine will build on the current on-going Phase 1 study for EMD 640744 by formulating the survivin-based vaccine in its DepoVax™.
|
|
|
|
The Michael J. Fox Foundation Awards $1.1M for Validation of Parkinson's Disease Therapeutic Targets
12 July 2010
The initiative provides intellectual and financial resources to the drug development pipeline, helping to advance potential PD drug targets toward clinical trials.
|
|
|
|
Bitop AG Reports that Ectoin® Reduces Symptoms of Acute Allergic Rhinitis
12 July 2010
Ectoin allergy nasal spray has been shown to significantly reduce symptoms of acute allergic rhinitis in a two-week observational study.
|
|
|
|
Kiadis Pharma Receives IND Approval From FDA to Start Pivotal Clinical Trial With ATIR(TM) in the United States
09 July 2010
Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR(TM) in the United States.
|
|
|
|
Proximagen Enters Into a Collaboration Agreement with the NIH
08 July 2010
Under the terms of the CRADA, NINDS will fully fund and carry out a double-blind, cross-over and placebo-controlled Phase II clinical trial in patients with epilepsy.
|
|
|
|
MorphoSys Receives Research Grant to Advance Anti-CD38 Cancer Program MOR202
07 July 2010
The Company plans to explore relevant biomarkers for the anti-CD38 approach in collaboration with Munich Technical University.
|
|
|
|
EyeTechCare Raises EUR 7.5M in a Second Funding Round and Speeds up its Development
07 July 2010
The funds will enable the company to complete the clinical trial of EyeOP1 medical device for the treatment of glaucoma.
|
|
|
|
Allogeneic Stem Cell Transplant Shows Promise for Treatment-Resistant CLL
07 July 2010
University of Heidelberg researchers publish study results in the journal Blood.
|
|
|
|
Quintiles Announces Clinical Research Partnership with the University Malaya Medical Centre
06 July 2010
Quintiles Prime Site program expands into Asia to accelerate clinical development.
|
|
|
|
Synexus Continues to Expand Clinical Trials Activities in Poland
06 July 2010
The new research centre in Gdynia will have the capacity for four full-time investigators and a wide range of diagnostic instruments.
|
|
|
|
SymBio Initiates Japan Phase 2 Trial of Bendamustine HCl (SyB L-0501) in Multiple Myeloma
05 July 2010
Patients in this multicenter open-label trial will receive the drug in combination with prednisolone.
|
|
|
|
Hybrigenics SA Brings its Fee-for-service Activities to Hybrigenics Services SAS
05 July 2010
Hybrigenics Services SAS will focus on further growth of fee-for-service businesses.
|
|
|
|
Drug Resistance Danger for Sleeping Sickness Treatments
05 July 2010
Drugs used to treat sleeping sickness must be used prudently to prevent the parasite acquiring resistance to current medicines, research shows.
|
|
|
|
Adverse Cardiovascular Events Reported in Testosterone Trial in Older Men
05 July 2010
The treatment phase of the trial has been stopped due to heart attacks and elevated blood pressure.
|
|
|